Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Health
Chiara Giordano

Groundbreaking twice-yearly jab could transform lives of high cholesterol sufferers by replacing daily statin tablets

File image. ( iStock/Getty )

A twice-yearly jab which replaces daily statins could be a “game changer” for millions of people with high cholesterol, scientists say.

A landmark study of 1,600 people over 18 months found that the injection halved the levels of “bad” cholesterol in the blood without any apparent side effects.

Doctors say the drug, called Inclisiran, showed “phenomenal” results and could transform the lives of millions of people who have to take statin tablets every day. 

It could also help lower the risk of a heart attack or stroke, they say.

Kausik Ray, professor of public health and consultant cardiologist at Imperial College London, led the study for the Medicines Company, which is developing the drug.

Presenting the findings to leading cardiologists at the European Society of Cardiology Congress in Paris, he said: “It’s a game changer to manage cholesterol. The convenience is key.”

It is hoped the jab could be on the market within about two years.

Researchers hope it will improve the lives of people living with high cholesterol who forget to take their statins or suffer side effects from the pills.

Prof Ray said it would initially be taken alongside daily statin tablets and could help up to about 700,000 people in the UK.

Mark Timney, chief executive of The Medicines Company, said: “We are excited at the prospect of bringing forward a remarkable, transformative advance in the treatment of cardiovascular disease.”

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.